Trump Team Weighs Pulling Funds for Moderna Bird Flu Vaccine
The US health officials are reevaluating a $590 million contract for bird flu shots awarded to Moderna Inc., citing a need to examine spending on messenger RNA-based vaccines due to concerns over government oversight and the Biden administration's failed pandemic preparedness. The review is part of a broader push to scrutinize vaccine production agreements, following criticism of the Trump administration's handling of the Covid-19 vaccine rollout. This move raises questions about the future of vaccine funding and the impact on public health.
- The shifting landscape of vaccine funding could have far-reaching implications for the development and distribution of life-saving treatments, particularly in light of ongoing concerns over global pandemics.
- Will the Trump administration's decision to reevaluate the Moderna contract signal a broader effort to reassess the role of government support in driving innovation and investment in vaccine research and development?